ArticleCureus2025
Hemophagocytic Lymphohistiocytosis: An 18-Year-Long Retrospective Single-Center Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHemophagocytic lymphohistiocytosis (HLH) is a disease characterized by systemic hyperinflammation, a so-called cytokine storm that leads to life-threatening complications. Up to this date, there is only one protocol available for patients with this pathology, and there are no second-line therapy protocols in cases of relapsed or refractory diseases. MATERIALS AND
methodsThis is a retrospective observational study of patients treated in the Department of Pediatric Hematology and Oncology, Pediatric Clinic No. 2, Emergency Hospital for Children, in Cluj-Napoca, Romania, between 2006 and 2024.
resultsThe population was represented by 23 patients, with two genetically confirmed familial HLH. The majority of the patients in the secondary HLH were due to Epstein-Barr virus (EBV) infection. Clinical symptoms were mainly represented by fever. Biologically, all patients had confirmed hemophagocytosis on bone marrow smear, while the majority presented with hyperferritinemia and cytopenias. The median time range from onset to diagnosis was 14 days. All patients were treated with the HLH-2004 protocol, and 17 received only induction, while others received continuation therapy plus associated therapies, such as antithymocyte globulin (ATG), rituximab, and anakinra. None of the patients underwent hematopoietic stem cell transplantation. We had a survival rate of 69.56%; five patients died, four with progressive disease and one due to complications.
conclusionHLH is considered a life-threatening disease; urgent diagnosis of both the disease and the underlying cause and treatment are essential for ensuring the best prognosis. Even so, there still are refractory diseases that need to be further studied in order to implement new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.